glp 1 agonist vs analog The current significance and prospects for the use of dual receptor agonism GLP-1/Glucagon Beyond glycemia: Comparing tirzepatide to

[DOI] [PubMed] [Google Scholar] 16.Lingvay I., Catarig A.M., Frias J.P., et al

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study

Islet amyloid toxicity: from genesis to counteracting mechanisms

10.1136/bmj.39489.470347.AD [DOI] [PMC free article] [PubMed] [Google Scholar] 84

Typically, GLP-1 receptor agonists are recommended for individuals with a BMI of 30 kg/m or higher, classified as obesity, or for those with a BMI of at least 27 kg/m who also have obesity-related health conditions such as hypertension, type 2 diabetes , or high cholesterol

It has become one of the most prescribed weight loss medications in the world, and the comparison between semaglutide and tirzepatide is one of the most searched topics in the GLP-1 space